论文部分内容阅读
目的 研究组织因子途径抑制物(TFPI)，尿激酶型纤溶酶原激活物(uPA)及其特异性受体(uPAR)和纤溶酶原激活物抑制物(PAI)rrrrrrrrn在恶性肿瘤中的表达水平和临床意义。rrrrrrrrn方法TFPI，uPA和uPAR采用酶联免疫法(ELISA)法，PAI采用发色底物法对44例恶性实体瘤(A1组)和30例急性白血病(AL，rrrrrrrrnA2组)进行检测。rrrrrrrrn结果(1)A1组较正常对照组(B组)TFPI，uPA，uPAR升高。(2)A2组较B组TFPI，uPAR升高，PAl降低。(3)组间比较：合并感rrrrrrrrn染组TFPI升高，出血组PAI降低，转移或复发组TFPI，uPA，uPAR和PAI均升高，1周内死亡组TFPI降低，uPA和PAR升高。rrrrrrrrn结论 恶性实体瘤和急性白血病存在不尽相同的抗凝，纤溶激活状态，其指标对病情和预后判断有指导意义。
Objective To investigate the effects of tissue factor pathway inhibitor (TFPI), urokinase-type plasminogen activator (uPA) and its specific receptor (uPAR) and plasminogen activator inhibitor (PAI) r r r r r n in malignant tumors and its clinical significance. Methods TFPI, uPA and uPAR enzyme-linked immunosorbent assay (ELISA) method, PAI chromogenic substrate method 44 cases of solid tumor (A1 group ) And 30 cases of acute leukemia (AL, r r r r r r r nA2 group) were detected. Results (1) Compared with normal control group (group A1), TFPI, uPA and uPAR increased in A1 group. (2) Compared with group B, TFPI and uPAR increased in group A2 and PAl decreased. (3) Comparison between groups: TFPI was increased in the combined group, the PAI in the bleeding group was decreased, and both TFPI, uPA, uPAR and PAI in the metastasis or relapse group Elevated TFPI in the death group within 1 week, uPA and PAR increased. Conclusions There are different anticoagulant and fibrinolytic activation states in malignant solid tumors and acute leukemias, and their indexes have guiding significance for the judgment of disease and prognosis.